Dynavax Technologies's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Dynavax Technologies (DVAX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Dynavax Technologies vs Its Competitors
- TTM: Trailing 12-month revenue of 331M vs 235,815M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+14.8% annualized vs trailing 12 months), vs decelerating (-12.5%) for its tracked peer group.
- Growth: Dynavax Technologies generated 17.7% revenue growth year over year in Q3 2025, vs -1.9% for its tracked competitors combined.
- Profitability: Its 28.4% net margin compares with 23.6% for the peer group.
- Peer revenue share: Dynavax Technologies accounted for 0.2% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $1.20M compares with $1.09M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DVAX Sales vs. its Competitors, Q3 2025
Dynavax Technologies reported revenue growth of 17.67 % year on year in Q3 2025, above its competitors' combined revenue change of -1.88 %.
With a net margin of 28.38 %, Dynavax Technologies achieved higher profitability than its competitors (23.55 %).
Dynavax Technologies generated 0.18 % of the combined sales of its peer group, up from 0.15 % a year earlier.
Dynavax Technologies vs. its Competitors, Q3 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Dynavax Technologies and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Dynavax Technologies Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Dynavax Technologies's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 17.7% for Dynavax Technologies. Dynavax Technologies's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Dynavax Technologies's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Dynavax Technologies Corporation | No | Yes | Yes | No |
| Competitors combined (46) | ||||
| High-Confidence Competitors (7) | ||||
| Similar Growth & Profitability (8) | 50.00 % (4 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DVAX Stock Performance relative to its Competitors
DVAX Stock Performance relative to High-Confidence Competitors
DVAX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Immunome Inc | 282.9% | Outperformed |
| 5 | Arcus Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Dynavax Technologies's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Dynavax Technologies's Comment on Competition and Industry Peers
Publicly Traded Peers of Dynavax Technologies Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Dynavax Technologies Corporation | 2,115.25 | 330.51 |
| Merck and Co Inc | 370,191.25 | 66,569.00 |
| Pfizer Inc | 163,652.48 | 63,696.00 |
| Bristol myers Squibb Company | 130,437.12 | 49,186.00 |
| Gsk Plc | 101,936.92 | 32,667.00 |
| Moderna Inc | 81,798.95 | 2,228.00 |
| SUBTOTAL | 981,752.19 | 236,802.05 |
Sign in to see all competitors of Dynavax Technologies Corporation.
Sources: Dynavax Technologies Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Dynavax Technologies Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Dynavax Technologies's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Curevo Vaccine | Named by the company | 85% |
| VBI Vaccines Inc. | Named by the company | 85% |
| Moderna, Inc. | Named by the company | 85% |
| GSK | Named by the company | 85% |
| Oncosec Medical Incorporated | Named by the company | 85% |
| BioNTech SE | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Merck | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Dynavax Technologies's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Dynavax Technologies's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Dynavax Technologies Corporation.
Dynavax Technologies's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Dynavax Technologies Corporation | 2,115 | 1,201,865 | -157,822 |
| Merck and Co Inc | 370,191 | 887,587 | 42,267 |
| Pfizer Inc | 163,652 | 849,280 | 58,267 |
| Bristol myers Squibb Company | 130,437 | 1,513,415 | 285,354 |
| Gsk Plc | 101,937 | 128,610,236 | 24,759,843 |
| Moderna Inc | 81,799 | 474,043 | -670,426 |
| PEERS TOTAL | 979,637 | 1,088,973 | 93,451 |
Sign in to see all peers for Dynavax Technologies Corporation.
Dynavax Technologies's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 23.60 % |
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | US 54.29 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Dynavax Technologies's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Dynavax Technologies's industry classification, broader than the peer set above. Market cap in millions of $.Dynavax Technologies ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Dynavax Technologies Corporation | 2,115 | 0.00 % |
Market cap and industry share for the rest of Dynavax Technologies's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-02-09.
Dynavax Technologies's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.17 % | 64.89 % (avg) | +18.3 pp |
| Operating Margin | 3.16 % | industry median | +45.7 pp |
| EBITDA Margin | -9.78 % | -7.21 % (avg) | -2.6 pp |
| Capital Intensity (Capex / Revenue) | 3.05 % | 4.92 % (avg) | -1.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Dynavax Technologies's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 2.6x | 4.5x | -1.9x |
| Return on Equity | -8.05 % | industry aggregate | -25.67 % |
| Return on Invested Capital | 0.73 % | -2.95 % (avg) | 3.68 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Dynavax Technologies's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -96.90 % | 500.00 % | 329.60 % | 12.72 % | 500.00 % | 64.60 % | -67.95 % | 19.87 % |
| Operating Margin | -29,359.33 % | -1,870.20 % | -382.87 % | -172.22 % | 30.67 % | 39.29 % | -16.01 % | -1.49 % |
| Return on Invested Capital | -29.87 % | -45.59 % | -50.94 % | -21.59 % | 24.78 % | 24.64 % | -2.42 % | -0.26 % |
| P/E | - | - | - | - | 47.7x | 6.2x | - | 79.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Dynavax Technologies's Strategic Group Map
Every company in Dynavax Technologies's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Dynavax Technologies is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Dynavax Technologies's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.05 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Dynavax Technologies's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Dynavax Technologies's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Dynavax Technologies's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Dynavax Technologies falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Dynavax Technologies's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 45.7 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+14.8% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 25.7 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (41.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-12.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Dynavax Technologies's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Dynavax Technologies Corporation | 1.09 | 8.77 | 0.47 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Gsk Plc | - | - | - |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Sign in to see all peers for Dynavax Technologies Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Dynavax Technologies's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Dynavax Technologies Corporation | Q3 2025 | +17.7 % | +53.0 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +5.2 % | -38.9 % |
Sign in to see all peers for Dynavax Technologies Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Dynavax Technologies's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Dynavax Technologies Corporation | Q3 2025 | +10.1 % | -8.1 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Sign in to see all peers for Dynavax Technologies Corporation.
Dynavax Technologies's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Dynavax Technologies Corporation | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Moderna Inc | - | - | - |
Sign in to see all peers for Dynavax Technologies Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Dynavax Technologies's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Dynavax Technologies Corporation | - | 6.40 |
| Merck and Co Inc | 120.87 | 5.56 |
| Pfizer Inc | 37.65 | 2.57 |
| Bristol myers Squibb Company | 14.02 | 2.65 |
| Gsk Plc | 17.83 | 3.12 |
| Moderna Inc | - | 36.71 |
| PEERS AVERAGE | 48.48 | 4.15 |
Sign in to see all peers for Dynavax Technologies Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.